Taysha Gene Therapies, Inc. TSHA 深 滬
等待開盤 08-19 09:30:00 美东时间
2.91
-0.030
-1.02%
華盛通- 最 高3.045
- 今 開2.96
- 成交量 162.12万股
- 最 低 2.88
- 昨 收 2.94
- 總市值 7.62亿
- 52周最高 3.31
- 市盈率 靜 --
- 換手率 0.62%
- 52周最低 1.05
- 委 比 -30.72%
- 總股本 2.62亿
- 歷史最高 33.35
- 量 比 0.56
- 振 幅 5.61%
- 歷史最低 0.50
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
08-13 09:10
Chardan Capital Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $9 to $10.
08-13 05:19
Taysha Gene Therapies Q2 EPS $(0.09) Misses $(0.08) Estimate, Sales $1.986M Beat $1.765M Estimate
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 9.76 percent. This is unchanged from the same period last year. The company
08-12 20:01
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
Taysha Gene Therapies plans to report its second-quarter 2025 financial results and host a corporate update call and webcast on August 12 at 8:30 AM ET. The company focuses on developing AAV-based gene therapies for severe CNS disorders, with its lead program TSHA-102 targeting Rett syndrome, a rare neurodevelopmental disease lacking effective treatments. Taysha aims to address unmet medical needs by leveraging its expertise and clinically proven...
08-05 20:05
B of A Securities Initiates Coverage On Taysha Gene Therapies with Buy Rating, Announces Price Target of $8
B of A Securities analyst Tazeen Ahmad initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and announces Price Target of $8.
07-11 20:20
Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock
Taysha Gene Therapies (NASDAQ:TSHA) underwent analysis by 10 analysts in the la...
07-01 20:04
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies granted stock options to purchase 401,000 shares to two new employees under its 2023 Inducement Plan. The options have an exercise price of $2.785, a 10-year term, and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the next three years, contingent on continued employment. The company focuses on developing AAV-based gene therapies for severe monogenic CNS diseases, ...
06-06 12:00
美股大行评级 | 潜在涨幅417.8%！RBC Capital上调Perspective Therapeutics目标价至16美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136940401951563776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Perspective Therapeutics(CATX)"跑赢大市"评级，目标价从15美元升至16美元</p> <p>• Canaccord Genuity：维持Taysha Gene Th
06-04 08:35
